Astellas’ Cresemba Review: Orphan Population With Unmet Need Vs. Limited Efficacy Data
This article was originally published in The Pink Sheet Daily
FDA’s Anti-Infective Drugs Advisory Committee will vote on whether efficacy and safety evidence support approval of Astellas’ antifungal isavuconazonium for two indications, one of which has no controlled data.
You may also be interested in...
FDA’s new drug development qualification process offers a pathway for outside groups to gain acceptance of specific biomarkers for regulatory purposes. FDA recently used the process to qualify a specific biomarker for a severe fungal infection.
Marks appeared to use the variable EUA bar to justify what many viewed as early mistakes by FDA during COVID-19, and to emphasize the importance of physician awareness of the strength of evidence used to authorize a drug.
From next-generation vaccine technology to safety data and global harmonization, what isn’t in the Vaccines and Related Biological Products Advisory Committee preview documents and on the 26 January meeting agenda may be just as important as what is.